Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07725939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Study acronym: SCALA
StatusRecruiting
PhasePhase 2
Started2026-07-27
View on ClinicalTrials.gov ↗

Amendment history

2026-08-26
Study Status, Contacts/Locations v4
Trial sites expanded: 4 → 7 locations
2026-08-13
Study Status, Contacts/Locations v3
Study sites1→3
2026-07-30
Study Status, Contacts/Locations v2
Recruitment opened
Start dateestimated 2026-07-31→confirmed 2026-07-27
Study sites0→1
2026-07-24
Study Identification, Study Status, Eligibility v1
Eligibility criteria+14 characters
[...] can be male or female. A male participant must agree to use contraception during the Intervention Periods and for at least 60 days af [...]
2026-07-21
Original filing
UCB Biopharma SRL
68 trials monitored
See 4 trials at risk
COPD
1,057 trials monitored
See 28 trials at risk
The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.
Trial Details
NCT Number NCT07725939
Lead Sponsor UCB Biopharma SRL
Conditions Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Enrollment 402 participants
Start Date 2026-07-27
Primary Completion 2029-06-29 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-09-25